About: Eltoprazine

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic or antiaggressive agent. It acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor. The drug is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan. Eltoprazine is or was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of February 2022. It was also under development for the treatment of psychotic disorders, but development for this indic

thumbnail
Property Value
dbo:abstract
  • Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic or antiaggressive agent. It acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor. The drug is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan. Eltoprazine is or was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of February 2022. It was also under development for the treatment of psychotic disorders, but development for this indication was discontinued. Eltoprazine was originated by Solvay and was developed by Elto Pharma, PsychoGenics, and Solvay. (en)
dbo:casNumber
  • 98224-03-4
dbo:chEMBL
  • 282614
dbo:fdaUniiCode
  • 510M006KO6
dbo:pubchem
  • 65853
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 22568440 (xsd:integer)
dbo:wikiPageLength
  • 4057 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1107566394 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 12 (xsd:integer)
dbp:casNumber
  • 98224 (xsd:integer)
dbp:chembl
  • 282614 (xsd:integer)
dbp:chemspiderid
  • 59265 (xsd:integer)
dbp:h
  • 16 (xsd:integer)
dbp:iupacName
  • 1 (xsd:integer)
dbp:n
  • 2 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:pubchem
  • 65853 (xsd:integer)
dbp:smiles
  • C1CNC2=C3COCCO3 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • WVLHGCRWEHCIOT-UHFFFAOYSA-N (en)
dbp:synonyms
  • DU-28,853; DU-28853 (en)
dbp:unii
  • 510 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic or antiaggressive agent. It acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor. The drug is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan. Eltoprazine is or was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of February 2022. It was also under development for the treatment of psychotic disorders, but development for this indic (en)
rdfs:label
  • Eltoprazine (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License